Being equitable about equivalents – Article from #1 2019
Has Lord Neuberger in Actavis introduced “an amorphous general inventive idea” test to determine UK patent infringement[…]
Second medical use claims – Article from #1 2019
ABSTRACT Second medical use patents and their claims do not only represent highly valuable inventions for both[…]
Do rules experience culture shock – Article from #1 2019
ABSTRACT In order to stimulate product development and innovation in the pharmaceutical industry, the United States Congress[…]
The patentability of Dosage Regimes – Article from #1 2019
ABSTRACT Despite the therapeutical benefits of dosage regimes, being granted and securing patent protection for these types[…]
Safeguarding public health – Article from #1 2019
INTRODUCTION In a world with an estimated population of 7.6 billion, 2 billion people lack access to[…]
In Pursuit of Robinson Crusoe – Article from #1 2019
Naming pharmaceuticals is a topic that has been thoroughly investigated and buzzed around, and where the world’s[…]
The CJEU clarifies – Article from #1 2019
INTRODUCTION Where to draw the line between the protection of new innovations within the pharmaceutical area, on[…]